Create Medicines raised $122 million to expand its in vivo CAR-T platform targeting cancers and autoimmune indications, the company said. The Series B round was co-led by Arch Venture Partners, Newpath Partners, and Hatteras Venture Partners, with participation from Alexandria Venture Investments and other backers. The Cambridge-based startup, formerly Myeloid Therapeutics, uses an mRNA-lipid nanoparticle approach designed to reprogram T cells, NK cells, and myeloid cells inside the body. Create reported it has dosed more than 50 patients across programs and said its dataset is the largest in the field. Clinically, Create last month dosed its first patient in the Phase 1/2 MT-304 trial, a HER2-directed CAR therapy for HER2-positive breast cancer and other solid tumors. The study also includes autoimmune cohorts exploring CD19- and BCMA-directed candidates. Ron Philip joined as executive chairman alongside the funding, as Create continues advancing “one-day manufacturing” concepts meant to differentiate engineered cell therapies from traditional manufacturing-heavy approaches.